A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
Phase 3 – large-scale trial before approval
Conditions:
Symptomatic genetic and familial dilated cardiomyopathy.
Sponsor: Kardigan Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from Baseline (Day 1) to Week 26 in left atrial function index (LAFI) in Cohort 1., Change from Baseline (Day 1) to Week 26 in peak oxygen consumption (pVO2) in Cohort 1.
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 178 participants
Interventions
Danicamtiv
Drug
Placebo tablets contain the same excipients as Danicamtiv tablets except the active substance.
БГ